Search

Staff Writer: Deileta Kamhunga It’s well established that there are serious inequities in cancer care and outcomes in the U.S. and around the globe. But are pivotal clinical trials including populations representative of all patients, particularly those who experience these inequities? Researchers set out to determine if clinical trials for lymphomas reflect the populations affected...

The American Society of Hematology (ASH), the world’s largest professional society concerned with the causes and treatment of blood disorders, today announced the election of three new members to its Executive Committee for terms beginning after the 2021 ASH Annual Meeting, December 11-14 in Atlanta, Georgia. Mohandas Narla, DSc, will serve a one-year term as...

In this MD Newsline exclusive interview with oncologist Dr. Onyemaechi Okolo, we discuss her treatment strategy for multiple myeloma. We also discuss the newest treatment for multiple myeloma and how to diversify cancer clinical trials. MD Newsline: What is your treatment strategy for multiple myeloma, and how is it tailored to each patient? How do these...

The transition from pediatric to adult treatment programs poses a challenge in the management of sickle cell disease. Developing transition programs with better knowledge of the factors that lead to transition success will be vital to improving patient outcomes.   Patients with sickle cell disease require lifelong treatment Transitioning from pediatric to adult care is a...

Multiple Myeloma is a type of cancer that impacts the plasma cells in the bone marrow. It is characterized by the proliferation and multiplication of these cells resulting in the production of antibodies that can potentially harm various systems within the body.  Diagnosing this cancer can be quite complex because its symptoms tend to manifest...

Obesity is a serious health condition that affects a significant portion of the population, leading to numerous health risks and complications. However, within the realm of obesity, there are different categories that vary in terms of severity and associated health risks. This article aims to clearly understand the difference between obesity and morbid obesity, including...

MONDAY, March 1, 2021 (HealthDay News) — Mortality is lowest with consumption of five servings of fruit and vegetables per day, according to a study published online March 1 in Circulation. Dong D. Wang, M.D., Sc.D., from Brigham and Women’s Hospital and Harvard Medical School in Boston, and colleagues followed 66,719 women from the Nurses’...

Individuals with poor- or intermediate-risk advanced sarcomatoid renal cell carcinoma may benefit from better first-line treatment outcomes with nivolumab and ipilimumab than with sunitinib.  Patients suffering from advanced sarcomatoid renal cell carcinoma (sRCC) have poor prognostic outcomes and limited treatment options. The first-line treatment of sRCC comprises nivolumab with ipilimumab (NIVO+IPI), which has greater efficacy...

The combination of MEDI0680 and durvalumab was well-tolerated and safe but did not show any significant improvement in effectiveness compared to nivolumab monotherapy, in this study. Renal cell carcinoma (RCC) accounts for 2–3% of all adult malignancies. Advanced or metastatic RCC has a poor prognosis, and standard-of-care treatment options are limited. Immunotherapy has emerged as...

Medically reviewed by Dr. Samuel Sarmiento, M.D., MPH on August 3, 2023 Insights from a recent study show the effectiveness and safety of narrowband UV-B phototherapy for children with vitiligo. If you’re a parent or caregiver of a child with vitiligo, this may offer some helpful information on this treatment option. Narrowband UV-B phototherapy can...